Purpose: We aimed to study the distribution of rotavirus genotypes (VP7 and VP4) and disease severity of rotavirus gastroenteritis prevalent in our community. Methods: Stool samples were collected from 156 children who were hospitalized with rotavirus gastroenteritis from December 2007 to June 2008. The disease severity of all patients was scored using the Vesikari scale. After extraction of ds-RNA of the rotavirus, cDNA synthesis using reverse transcription and polymerase chain reaction (RT-PCR) and multiplex PCR was performed. Following this, the final identification of genotypes was performed. Results: Of the 156 samples, VP7(G) and VP4(P) genotypes were identified in 147 (94.2%) and 140 (89.7%) samples, respectively. G1 (116 of 147 samples; 78.9%) and P[8] (137 of 140 samples; 97.9%) were the most prevalent, respectively. Of the 138 samples identified of combination types of VP7 and VP4, G1P[8] (111 samples; 80.4%) was the most prevalent. Other combination types varied with very low distribution rates. 9.4% of genotypes were not included in the new vaccines. The disease severity score was 11.8±3.3 (mean±2SD). The distribution of disease severity was mild or moderate in 37.8% and severe in 62.2% of patients.
INTRODUCTION
In 1998, the quadrivalent Rheshus-based recombinant rotavirus vaccine (RRV-TV; Rotashield Ⓡ , Wyeth Lederle Vaccines, Philadelphia, USA) received approval from the USA Food and Drug Administration (FDA) and was successfully commercialized. However, in 1999 it was withdrawn from the market because of the high correlation rate of intussusception development after immunization 1) . Efforts for the development of new rotavirus vaccines continued after that 2, 3) . Finally, worldwide studies of human rotavirus attenuated vaccine (Rotarix Surface proteins of the rotavirus defining the genotypes are the 23 VP7 (G genotype) and 28 VP4 (P genotype)
genes. Of the 42 combinations of G and P genotypes, G1P [8] , G2P [4] , G3P [8] , G4P [8] and G9P [8] are common genotype combinations 6, 7) . Combination of G1 and P [8] is the most prevalent genotype globally.
Rotarix
Ⓡ is an attenuated live vaccine produced in the tissue incubator using rotavirus isolated from infected humans. It consists of G1 and P1a [8] . The efficacy for the prevention of severe rotavirus gastroenteritis and hospitalization caused by rotavirus infection was as high as 85% 4) . RotaTeq Ⓡ is a pentavalent recombinant vaccine produced from the combination of G1∼4P and P [8] of the human and bovine rotavirus. It results in a high production rate of IgA in humans 8) . The efficacy for the prevention of overall and severe rotavirus gastroenteritis is 74% and 98%, respectively 5) .
Although these two new vaccines have a high prevention rate for severe rotavirus gastroenteritis, there are only a few reports on the distribution of disease severity and rotavirus genotypes in children with rotavirus gastroenteritis. Therefore, we conducted a prospective study to address this issue. 
MATERIALS

Reverse transcription and first PCR amplification
This step was immediately performed after the extraction of rotavirus ds-RNA using reverse transcriptase polymerase chain reaction (RT-PCR) and multiplex PCR, based on the method described by Gouvea et al 10) and
Gentsch et al 11) , using the same primers designed in their study.
Second PCR amplification (multiplex PCR)
For VP7 genotyping, RT-PCR with the primers Beg9 
Electrophoretyping of PCR products of Ro-
tavirus VP7 (G type) and VP4 (P types) bp (primer 5T1).
Ethics statement
This study was performed with the permission of the internal ethics committee of Jeju National University
Hospital (JNUH-IRB-06-1). We received written informed consent to participate from the parents of each of the 156 children.
RESULTS
The sex distribution of the 156 children used in this study was 76 male and 80 female. G2 in 2 (1.4%) and G8 in 1 patient (0.7%). For VP4 genotype distribution in the 140 patients (Fig. 2) , P [8] was the most common, identified in 137 patients (97.9%) followed by P [4] in 3 patients (2.1%). There was no distribution identified for P [6] , P [9] and P [10] .
The combination types of VP7 and VP4 was identified in 138 of 156 patients. In these 138 patients ( (mean±2SD) ( Table 3 ). In distribution of disease severity, the severe state (Vesikari scale≥11) was as high as 62.2% (Table 3) .
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This result was similar with the Givon-Lavi et al. report
in that 756 (76.6%) of 987 rotavirus infected patients were classified in the severe state 13) . They also reported that the body temperature and serum levels of rotavirus antigen were higher in the severe state. Serum antigen level was considered one of the factors affeting disease severity, but we did not check antigenicity in patient serum.
There are two methods for the scoring of disease severity of rotavirus gastroenteritis, which include the 20-point Vesikari scale 9) and the 24-point Clark scale 3) .
A severe state is defined as a score of more than 11 points on the Vesikari scale and more than 16 points on the Clark scale. Givon-Lavi et al. reported that only 35%
of patients that were scored as being in the severe state by the Vesikari scale were also scored as severe by the Clark scale. On the contrary, severe states using the Clark scale were all scored as severe by the Vesikari scale.
Therefore, the Clark scale can be considered more strict than the Vesikari scale to evaluate disease severity. Based on this, when the reports were compared, both scales needed to be considered. When we applied the results from Givon-Lavi et al. 9) to our study, the percentage of the severe state by the Clark scale was estimated to be 21% of 143 patients. In the clinical study of Rotarix 4) , the change of the Vesikari scale was used as one of the variables for the evaluation of vaccine efficacy. In the RotaTeq study 5) , the change observed in the Clark scale was used.
We analyzed the differences observed in disease severity distribution dependent on VP7 and VP4 genotypes.
However, G1P [8] was as high as 80.4% whereas the other genotype combination in each was less than 5%. We did not do further analysis on the severity distribution since it was considered to be less informative. Aupiais et al. 14) reported that the difference in disease severity between the G1 and G9 serotype was not significant in their study.
On the other hand, Linhares et al. 15) reported more severe disease associated with serotype G9 in Latin America.
In our study, there was no correlation between disease severity and dehydration grade as a major complication of rotavirus gastroenteritis on admission. 19) report in Seoul, G1P [8] was the most common genotype (80.4%) in our study (Table 2 ). On the other hand, Han et al. 20) reported the most frequent combination of genotypes was G9P [8] (32.1%) followed by G1P [8] (20.7%) in Seoul. Bishop 21) insisted that the efficacy of the two new vaccines for genotypes not included in these vaccines may be reduced. Genotypes not included in the new vaccines represented 9.4% in our study (Table 2) .
Recently, reports indicated that the epidemic peak of rotavirus gastroenteritis moved to spring from the winter 16, 22) . Our previous study 23) also revealed a peak in spring.
Rotavirus infection can cause afebrile convulsion 18, 19, 24, 25) , but no such case was observed in our study. Nosocomial infection contributed to less than 1% of all rotavirus infected children 26) . In particular, nosocomial infections are problematic in neonates and G4P [6] is the major genotype that causes these infections 27) . However, these could not be analyzed in our study due to the small number of neonatal cases.
One limitation in our study was that the period of recruiting patients was too short and may not represent the change of genotype prevalance over many years.
Another limitation was the exclusion for outpatients, which may cause higher disease severity scores than what actually occurs.
In conclusion, the most prevalent genotype combination of rotavirus was G1P [8] 
